{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041597","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.748353+00:00","generated_at":"2026-06-11T14:42:06.206292+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Iterum Therapeutics Q2 net loss $12.2M; REASSURE trial 50% enrolled, topline data expected Q2 2024","bullets":["Net loss $12.2M in Q2 2023 vs $6.7M in Q2 2022; non-GAAP net loss $10.0M.","R&D expense $9.0M (up from $4.0M) driven by REASSURE trial costs; G&A $1.9M (down from $4.1M).","Cash and short-term investments $44.7M; cash runway into Q3 2024.","REASSURE trial: 50% enrollment (target 1,966 patients); enrollment completion expected Q1 2024, topline data Q2 2024.","New Japanese patent for oral sulopenem bilayer tablet granted; expires no earlier than 2039."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041597","json":"https://secwatch.observer/filing/0000950170-23-041597.json","markdown":"https://secwatch.observer/filing/0000950170-23-041597.md","text":"https://secwatch.observer/filing/0000950170-23-041597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023041597/0000950170-23-041597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023041597/itrm-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:42:06.206292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48a4d60513a8ecafb76f7731a9973a0575e06e08","claim":"Iterum Therapeutics plc reported quarter ended June 30, 2023 results: net income $12.2 million.","evidence_excerpt":"Iterum Therapeutics plc issued a press release announcing its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023041597/0000950170-23-041597-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"$12.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}